IP Library Granted Patent US 7,118,915
Granted Patent B2
US 7,118,915 · App. 10/491,001 · Granted Oct 10, 2006

Muteins of apolipoprotein D

Assignee: Pieris Proteolab AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,118,915
App. No.
10/491,001
Granted
Oct 10, 2006
Kind
B2
Abstract

A method for generating a mutein of human apolipoprotein D having detectable affinity to a given non-natural ligand of apolipoprotein D is disclosed, which comprises the steps of: (a) subjecting the apolipoprotein D to mutagenesis at the sequence positions 34 to 38, 60, 62 to 66, 68, 89 to 93, 115, 117 to 121, and 123 resulting in a plurality of muteins of apolipoprotein D; and (b) enriching resulting muteins having binding affinity for a given ligand from the plurality of muteins by selection, and/or isolating said mutein. Muteins of apolipoprotein D obtainable by this method are also disclosed.

Claims (10)

1. A method for generating a mutein of human apolipoprotein D having detectable affinity to a given non-natural ligand of apolipoprotein D, comprising:

subjecting apolipoprotein D to mutagenesis at positions 34 to 38, 60, 62 to 66, 68, 89 to 93, 115, 117 to 121, and 123 of SEQ ID NO.: 22, resulting in a plurality of muteins of apolipoprotein D; and

selecting and/or isolating any resulting muteins having binding affinity for a given ligand from the plurality of muteins.

2. A method according to claim 1 , wherein said selecting comprises:

providing as given ligand a compound which is selected from the group consisting of a chemical compound in free or conjugated form that exhibits features of an immunological hapten, a peptide, a protein or another macromolecule,

contacting the plurality of muteins with said ligand in order to allow formation of complexes between said ligand and muteins having binding affinity for said ligand, and

removing muteins having no or no substantial binding affinity.

3. A method according to claim 1 , wherein the ligand is a protein.

4. A method according to claim 1 , wherein the selecting is carried out under competitive conditions.

5. A method according to claim 1 , wherein a nucleic acid coding for the plurality of muteins of apolipoprotein D, which nucleic acid results from mutagenesis, is operably fused at the 3′ end with a gene coding for the coat protein pIII of a filamentous bacteriophage of the M13-family or for a fragment of this coat protein, in order to select at least one mutein for the binding of the given ligand.

Assignments (3)
CHANGE OF NAME Recorded Aug 23, 2016
From: PIERIS AG
To: PIERIS PHARMACEUTICALS GMBH
Reel/Frame 039785/0233 →
CHANGE OF NAME Recorded May 4, 2007
From: PIERIS PROTEOLAB AG
To: PIERIS AG
Reel/Frame 019251/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2006
From: VOGT, MARTIN; SKERRA, ARNE
To: PIERIS PROTEOLAB AG
Reel/Frame 017861/0668 →
Continuity (1)
Related Publication 20050106660A1 · May 19, 2005